Jumping Mechanography is a Suitable Complementary Method to Assess Motor Function in Ambulatory Boys with Duchenne Muscular Dystrophy

Abstract

Objective The number of clinical trials for Duchenne muscular dystrophy (DMD) has increased substantially lately, therefore appropriate clinical instruments are needed to measure disease progression and drug efficacy. Jumping mechanography is a medical diagnostic method for motion analysis, which allows to quantify physical parameters. In this study, we compared mechanography with timed function tests (TFTs).

Methods 41 ambulatory DMD patients performed a total of 95 chair rising tests (CRT) and a total of 76 single two-legged jumps (S2LJ) on a mechanography ground reaction force platform. The results were correlated with a 6-minute walk test (6MWT) and the time required to run 10 meters, stand up from a supine position, and climb four stairs, all performed in the same setting.

Results Our measurements show a high correlation between mechanography and the TFTs: S2LJ/10-m run, r = 0.62; CRT/10-m run, r = 0.61; S2LJ/standing up from supine, r = 0.48; CRT/standing up from supine, r = 0.58; S2LJ/climb four stairs, r = 0.55; CRT/climb four stairs, r = 0.51. The correlation between mechanography and the 6MWT was only moderate with r = 0.38 for S2LJ/6MWT and r = 0.39 for CRT/6MWT.

Interpretation Jumping mechanography is a reliable additional method, which can be used for physical endpoint measurements in clinical trials. We confirmed our assumption, that the method provides additional information concerning performance at movement with higher power output. We suggest using the S2LJ as a first-choice tandem tool combined with the 6MWT. In patients with higher disability, the CRT is an alternative measuring method, because with the progression of the disease this is longer feasible.

Keywords

jumping mechanography - Duchenne muscular dystrophy - outcome measure - chair rising test - single two-legged jump - timed function tests

Publikationsverlauf

Eingereicht: 24. August 2020

Angenommen: 11. Dezember 2020

Artikel online veröffentlicht:
11. März 2021

• References

• 1 Zubrzycka-Gaarn EE, Bulman DE, Karpati G. et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988; 333 (6172): 466-469
• 2 Emery AE. The muscular dystrophies. Lancet 2002; 359 (9307): 687-695
• 3 Brooke MH, Fenichel GM, Griggs RC. et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989; 39 (04) 475-481
• 4 Villanova M, Kazibwe S. New survival target for Duchenne muscular dystrophy. Am J Phys Med Rehabil 2017; 96 (02) e28-e30
• 5 El-Aloul B, Altamirano-Diaz L, Zapata-Aldana E. et al. Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Neuromuscul Disord 2017; 27 (01) 4-14
• 6 Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016; (05) CD003725
• 7 Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993; 90 (08) 3710-3714
• 8 Petrof BJ. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol Cell Biochem 1998; 179 (1-2): 111-123
• 9 McDonald CM, Sajeev G, Yao Z. et al; ACT DMD Study Group and the Tadalafil DMD Study Group. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve 2020; 61 (01) 26-35
• 10 Campbell C, Barohn RJ, Bertini E. et al; PTC124-GD-007-DMD Study Group, ACT DMD Study Group, Clinical Evaluator Training Groups. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res 2020; 9 (14) 973-984
• 11 Charleston JS, Schnell FJ, Dworzak J. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 2018; 90 (24) e2146-e2154
• 12 Sheridan C. Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance. Nat Biotechnol 2016; 34 (07) 675-676
• 13 Le Guiner C, Servais L, Montus M. et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun 2017; 8: 16105
• 14 Robinson-Hamm JN, Gersbach CA. Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Hum Genet 2016; 135 (09) 1029-1040
• 15 Reinig AM, Mirzaei S, Berlau DJ. Advances in the treatment of Duchenne muscular dystrophy: new and emerging pharmacotherapies. Pharmacotherapy 2017; 37 (04) 492-499
• 16 McDonald CM, Henricson EK, Abresch RT. et al; PTC124-GD-007-DMD Study Group. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013; 48 (03) 343-356
• 17 Markovic G, Dizdar D, Jukic I, Cardinale M. Reliability and factorial validity of squat and countermovement jump tests. J Strength Cond Res 2004; 18 (03) 551-555
• 18 Tsubaki A, Kubo M, Kobayashi R, Jigami H, Takahashi HE. Normative values for maximum power during motor function assessment of jumping among physically active Japanese. J Musculoskelet Neuronal Interact 2009; 9 (04) 263-267
• 19 Veilleux LN, Rauch F. Reproducibility of jumping mechanography in healthy children and adults. J Musculoskelet Neuronal Interact 2010; 10 (04) 256-266
• 20 Matheson LA, Duffy S, Maroof A, Gibbons R, Duffy C, Roth J. Intra- and inter-rater reliability of jumping mechanography muscle function assessments. J Musculoskelet Neuronal Interact 2013; 13 (04) 480-486
• 21 Rittweger J, Schiessl H, Felsenberg D, Runge M. Reproducibility of the jumping mechanography as a test of mechanical power output in physically competent adult and elderly subjects. J Am Geriatr Soc 2004; 52 (01) 128-131
• 22 Buehring B, Belavy DL, Michaelis I, Gast U, Felsenberg D, Rittweger J. Changes in lower extremity muscle function after 56 days of bed rest. J Appl Physiol (1985) 2011; 111 (01) 87-94
• 23 Lang I, Busche P, Rakhimi N, Rawer R, Martin DD. Mechanography in childhood: references for grip force, multiple one-leg hopping force and whole body stiffness. J Musculoskelet Neuronal Interact 2013; 13 (02) 227-235
• 24 Fricke O, Weidler J, Tutlewski B, Schoenau E. Mechanography--a new device for the assessment of muscle function in pediatrics. Pediatr Res 2006; 59 (01) 46-49
• 25 Busche P, Rawer R, Rakhimi N, Lang I, Martin DD. Mechanography in childhood: references for force and power in counter movement jumps and chair rising tests. J Musculoskelet Neuronal Interact 2013; 13 (02) 213-226
• 26 Shere C, Fuggle NR, Edward MH. et al. Jumping joints: the complex relationship between osteoarthritis and jumping mechanography. Calcif Tissue Int 2020; 106 (02) 115-123
• 27 Min TJ, Cho J, Ha YC. et al. Correlation between mechanography and clinical parameters at six months after hip fracture surgery. Ann Rehabil Med 2019; 43 (06) 642-649
• 28 Rupp T, Butscheidt S, Jähn K. et al. Low physical performance determined by chair rising test muscle mechanography is associated with prevalent fragility fractures. Arch Osteoporos 2018; 13 (01) 71
• 29 Fitzgerald JS, Johnson L, Tomkinson G, Stein J, Roemmich JN. Test-retest reliability of jump execution variables using mechanography: a comparison of jump protocols. J Sports Sci 2018; 36 (09) 963-969
• 30 Hannam K, Hartley A, Clark EM, Aihie Sayer A, Tobias JH, Gregson CL. Feasibility and acceptability of using jumping mechanography to detect early components of sarcopenia in community-dwelling older women. J Musculoskelet Neuronal Interact 2017; 17 (03) 246-257
• 31 Houghton KM, Macdonald HM, McKay HA, Guzman J, Duffy C, Tucker L. LEAP Study Investigators. Feasibility and safety of a 6-month exercise program to increase bone and muscle strength in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2018; 16 (01) 67
• 32 Maratova K, Soucek O, Matyskova J. et al. Muscle functions and bone strength are impaired in adolescents with type 1 diabetes. Bone 2018; 106: 22-27
• 33 Bös K, Worth A, Opper E. et al. Motorik-Modul: eine Studie zur motorischen Leistungsfähigkeit und körperlich-sportlichen Aktivität von Kindern und Jugendlichen in Deutschland; Abschlussbericht zum Forschungsprojekt. ISBN 978-3-8329-4498-8
• 34 Runge M, Rittweger J, Russo CR, Schiessl H, Felsenberg D. Is muscle power output a key factor in the age-related decline in physical performance? A comparison of muscle cross section, chair-rising test and jumping power. Clin Physiol Funct Imaging 2004; 24 (06) 335-340
• 35 Ward KA, Das G, Berry JL. et al. Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab 2009; 94 (02) 559-563
• 36 Vill K, Ille L, Blaschek A. et al. Jumping mechanography as a complementary testing tool for motor function in children with hereditary motor and sensory neuropathy. Neuropediatrics 2017; 48 (06) 420-425
• 37 Dietzel R, Gast U, Heine T, Felsenberg D, Armbrecht G. Cross-sectional assessment of neuromuscular function using mechanography in women and men aged 20-85 years. J Musculoskelet Neuronal Interact 2013; 13 (03) 312-319
• 38 Duran I, Martakis K, Stark C. et al. Experience with jumping mechanography in children with cerebral palsy. J Musculoskelet Neuronal Interact 2017; 17 (03) 237-245
• 39 Bartels B, de Groot JF, Terwee CB. The six-minute walk test in chronic pediatric conditions: a systematic review of measurement properties. Phys Ther 2013; 93 (04) 529-541
• 40 Komi PV. Stretch-shortening cycle: a powerful model to study normal and fatigued muscle. J Biomech 2000; 33 (10) 1197-1206